Previous 10 | Next 10 |
Heron Therapeutics (NASDAQ: HRTX ): Q2 GAAP EPS of -$0.63 in-line. Revenue of $36.7M (+112.1% Y/Y) beats by $5.27M . Shares +1% PM. Press Release More news on: Heron Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
SAN DIEGO , Aug. 5, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced fina...
To review, Heron (NASDAQ: HRTX ) had a rough early May after receipt of a CRL for its HTX-011. More news on: Heron Therapeutics, Inc., Quick stock ideas, Healthcare stocks news, Read more ...
Editor's note: Seeking Alpha is proud to welcome William Affleck as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Editor's note: ...
SAN DIEGO , June 13, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced tha...
The following slide deck was published by Heron Therapeutics, Inc. in conjunction with this Read more ...
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Heron Therapeutics, Inc. (“Heron Therapeutics” or the “Company”) (NASDAQ: HRTX ) investors concerning the Company and its officers’ possible violations of feder...
NEW YORK, NY / ACCESSWIRE / June 5, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Heron Therapeutics, Inc. ("Heron") or the ("Company") (NASDAQ: HRTX) of the August 5, 2019 deadline to seek the role of lead plaintiff in a federal securities cla...
Point Roberts, WA and Delta, BC - June 4, 2019 (Investorideas.com Newswire) Investorideas.com, a leading investor news resource covering biotechnology and pharmaceutical stocks releases a sector snapshot reporting on the continued growth in OTC analgesics as consumers look for more affordable an...
SAN DIEGO , May 29, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire SAN DIEGO , May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechn...